1. |
李连第,张思维,鲁凤珠,等. 中国恶性肿瘤死亡谱及分类构成研究 [J]. 中华肿瘤杂志, 1997; 19(5)∶323.
|
2. |
GraslKraupp B, RuttkayNedecky B, Mullauer L, et al. Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression [J]. Hepatology, 1997; 25(4)∶906.
|
3. |
Terada T, Nakanuma Y. Expression of apoptosis, proliferation cell nuclear antigen, and apoptosisrelated antigen (bcl2, cmyc, Fas, Lewisy, and p53) in human cholangiocarcinomas and hepatocellular carcinomas [J]. Pathol Int,1996; 46(10)∶764.
|
4. |
Farber E. Hepatocyte proliferation in stepwise development of experimental liver cell cancer [J]. Dig Dis Sci, 1991; 36(7)∶973.
|
5. |
Edmondson HA,Steiner PE. Primary carcinoma of liver. A study of 100 cases among 48 900 necropsies [J]. Cancer, 1954; 7∶462.
|
6. |
Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis [J]. Am J Clin Pathol, 1995; 103(3)∶300.
|
7. |
Soini Y, Virkajarvi N, Lehto VP, et al. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival [J]. Br J Cancer, 1996; 73(9)∶1025.
|
8. |
Bravo R, Frank R, Blundell PA, et al.Cyclin/PCNA is the auxiliary protein of DNA polymerasedelta [J]. Nature, 1987; 326(6112)∶515.
|
9. |
阮幼冰,武忠弼,杨木兰,等. 大鼠肝癌发生过程中增殖细胞核抗原及表达 [J]. 中华病理学杂志,1996; 25(1)∶39.
|
10. |
Hino N, Higashi T, Nouso K, et al. Proliferating cell nuclear antigen and grade of malignancy in small hepatocellular carcinomaevaluation in USguided specimens [J]. Hepatogastroenterology, 1997; 44(13)∶245.
|
11. |
Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer antiapoptosis gene survivin in human and mouse differentiation [J]. Am J Pathol,1998; 152(1)∶43.
|
12. |
Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma [J]. Nat Med, 1997; 3(8)∶917.
|
13. |
Tamm I, Wang Y, Sausville E, et al.IAPfamily protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs [J]. Cancer Res, 1998; 58(23)∶5315.
|
14. |
Sarela AI, Macadam RC, Farmery SM, et al. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma [J]. Gut, 2000; 46(5)∶645.
|
15. |
Monzo M, Rosell R, Felip E, et al. A novel antiapoptosis gene: Reexpression of survivin messenger RNA as a prognosis marker in nonsmallcell lung cancer [J]. J Clin Oncol, 1999; 17(7)∶2100.
|
16. |
Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J]. Oncogene, 2000; 19(5)∶617.
|
17. |
Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with CDK4 to resist Fasmediated cell death [J]. Oncogene, 2000; 19(10)∶1346.
|
18. |
Ishida M, Gomyo Y, Tatebe S, et al. Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferasemediated dUTPbiotin nick end labelling [J]. Virchows Arch, 1996; 428(4-5)∶229.
|
19. |
Shin S, Sung BJ, Cho YS, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase3 and 7 [J]. Biochemistry, 2001; 40(4)∶1117.
|
20. |
Ito Y, Matsuura N, Sakon M, et al. Both cell proliferation and apoptosis significantly predict shortened diseasefree survival in hepatocellular carcinoma [J]. Br J Cancer, 1999; 81(4)∶747.
|